Results 71 to 80 of about 164,596 (212)

Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs [PDF]

, 2009
This review illustrates notable recent progress in the field of medicinal bioinorganic chemistry as many new approaches to the design of innovative metal-based anticancer drugs are emerging.
Aird, Ang, Barnard, Barnes, Bednarski, Bergamo, Bergamo, Bindoli, Campone, Chatterjee, Che, Chen, Chen, Chen, Chen, Choy, Clarke, Cordier, Desoize, Detty, Dougan, Ernst, Failes, Farrer, Feazell, Fricker, Gabbiani, Gunatilleke, Hall, Hambley, Hamelers, Henderson, Hillard, Hotze, Hotze, Jakupec, Jakupec, Junicke, Kelland, Kostenich, Kostova, Kostrhunova, Li, Mackay, Mackay, Meggers, Mosi, Nguyen, Noor, Oliveira, Ott, Ott, Ott, Peacock, Peacock, Peacock, Peter J. Sadler, Petzold, Petzold, Powis, Rademaker-Lakhai, Sabine H. van Rijt, Sadler, Saggioro, Sergeant, Sessler, Sharman, Shaw, Sherman, Smalley, Storr, Urig, van Rijt, Vessieres, Wang, Wang   +75 more
core   +1 more source

Long non-coding RNAs MACC1-AS1 and FOXD2-AS1 mediate NSD2-induced cisplatin resistance in esophageal squamous cell carcinoma

Molecular Therapy: Nucleic Acids, 2021
The nuclear receptor-binding SET domain (NSD) protein family encoding histone lysine methyltransferases is involved in cancer progression. However, the role of NSDs in esophageal squamous cell carcinoma (ESCC) remains unclear.
Wenhua Xue, Zhibo Shen, Lifeng Li, Yuanyuan Zheng, Dan Yan, Quancheng Kan, Jie Zhao   +6 more
doaj   +1 more source

Preclinical Evaluation of Ureidosulfamate Carbonic Anhydrase IX/XII Inhibitors in the Treatment of Cancers [PDF]

, 2019
Carbonic anhydrases (CAs) are a family of enzymes involved in the pH regulation of metabolically active cells/tissues. Upregulation of the CAIX/XII isoforms is associated with hypoxic tumours and clinically linked with malignant progression, treatment ...
Gieling, Roben, Williams, Kaye J.
core   +2 more sources

MTMR6 downregulation contributes to cisplatin resistance in oral squamous cell carcinoma

Cancer Cell International
Background The therapeutic effectiveness of cisplatin, a widely used chemotherapy drug for oral squamous cell carcinoma (OSCC), is often compromised by resistance, making it difficult to predict treatment outcomes.
Kah Young Lee, Su Young Oh, Heon-Jin Lee, Tae-Geon Kwon, Jin-Wook Kim, Chang-Geol Shin, Su-Hyung Hong, So-Young Choi   +7 more
doaj   +1 more source

Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells [PDF]

, 2015
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and incurable disease. Poor prognosis is due to multiple reasons, including acquisition of resistance to gemcitabine, the first-line chemotherapeutic approach.
Bielli, P, Calabretta, S, Capurso, G, DELLE FAVE, Gianfranco, Fendrich, V, Passacantilli, I, Pilozzi, Emanuela, Sette, C.   +7 more
core   +2 more sources

miR-133b reverses cisplatin resistance by targeting GSTP1 in cisplatin-resistant lung cancer cells

International Journal of Molecular Medicine, 2018
MicroRNAs play a critical role in chemoresistance and are implicated in various biological and pathological processes of cells. The objective of the present study was to explore the role of miR‑133b and its mechanism in the regulation of cisplatin resistance and tumor progression in cisplatin‑resistant non‑small cell lung cancer (NSCLC) cells.
Lin, Chen, Xie, Liyi, Lu, Yan, Hu, Zhihuang, Chang, Jianhua   +4 more
openaire   +3 more sources

Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer

Brazilian Journal of Medical and Biological Research, 2013
Cisplatin resistance remains one of the major obstacles when treating epithelial ovarian cancer. Because oxaliplatin and nedaplatin are effective against cisplatin-resistant ovarian cancer in clinical trials and signal transducer and activator of ...
W.J. Sheng, H. Jiang, D.L. Wu, J.H. Zheng   +3 more
doaj   +1 more source

Unusual DNA binding modes for metal anticancer complexes [PDF]

, 2009
DNA is believed to be the primary target for many metal-based drugs. For example, platinum-based anticancer drugs can form specific lesions on DNA that induce apoptosis.
Pizarro, Ana M., Sadler, P. J.
core   +1 more source

Characterization of a Cisplatin-resistant HeLa subline and mechanisms of cisplatin-resistance.

Journal of Japan Society for Oral Tumors, 1990
ヒト口腔領域由来腫瘍細胞, UEDA, NAKATA, KANETSUKI, HSG, HSY, 子宮頸部由来HeLa, 外陰部由来A431の7種の培養細胞を用いてシスプラチンに対する感受性を検索した。腺癌細胞は扁平上皮癌細胞に比べてシスプラチンに対して高い感受性を示し, 唾液腺腺癌に化学療法が有用であると示唆された。また, 一方扁平上皮癌細胞は自然耐性を示した。シスプラチンに感受性の高い細胞は高い細胞内シスプラチン濃度を示し, シスプラチンの取り込みは殺細胞効果を反映すると考えられた。シスプラチン耐性のメカニズムを解明するためにHeLa細胞を用いてシスプラチン耐性細胞を分離した (HeLaDDP) 。同細胞はシスプラチン非存在下17ケ月間継代培養した後も約4.3倍の安定した耐性を発現していた ...
Miho Furue, Tetsuji Okamoto, Kazuaki Takada   +2 more
openaire   +2 more sources

LTBP2 regulates cisplatin resistance in GC cells via activation of the NF-κB2/BCL3 pathway

Genetics and Molecular Biology
Gastric cancer (GC) often develops resistance to cisplatin treatment, but while latent transforming growth factor β-binding protein (LTBP2) is recognized as a potential regulator in GC, its specific role in cisplatin resistance is not fully understood ...
Jun Wang, Wenjia Liang, Xiangwen Wang, Zhao Chen, Lei Jiang   +4 more
doaj   +1 more source